Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Enterprise Value: 2016-2025

Historic Enterprise Value for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $557.4 million.

  • Akebia Therapeutics' Enterprise Value rose 128.85% to $557.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.8 million, marking a year-over-year increase of 113.89%. This contributed to the annual value of $362.7 million for FY2024, which is 90.20% up from last year.
  • As of Q3 2025, Akebia Therapeutics' Enterprise Value stood at $557.4 million, which was down 31.92% from $818.7 million recorded in Q2 2025.
  • Akebia Therapeutics' Enterprise Value's 5-year high stood at $818.7 million during Q2 2025, with a 5-year trough of -$86.7 million in Q3 2022.
  • Its 3-year average for Enterprise Value is $317.3 million, with a median of $243.6 million in 2024.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 129.33% in 2022, then skyrocketed by 1,116.05% in 2023.
  • Quarterly analysis of 5 years shows Akebia Therapeutics' Enterprise Value stood at $245.6 million in 2021, then plummeted by 93.62% to $15.7 million in 2022, then skyrocketed by 1,116.05% to $190.7 million in 2023, then spiked by 90.20% to $362.7 million in 2024, then skyrocketed by 128.85% to $557.4 million in 2025.
  • Its Enterprise Value was $557.4 million in Q3 2025, compared to $818.7 million in Q2 2025 and $340.2 million in Q1 2025.